# LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer

> **NCT01485744** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 39 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan

## Key facts

- **NCT ID:** NCT01485744
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2019-11
- **Final completion:** 2019-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01485744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01485744, "LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01485744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*